T-91825-PPI-0903M-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemET-91825Cat.No.:HY-105049CASNo.:189345-04-8Synonyms:PPI-0903M分?式:C??H??N?O?S?分?量:604.7作?靶點:Bacterial作?通路:Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:100mg/mL(165.37mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.6537mL8.2686mL16.5371mL5mM0.3307mL1.6537mL3.3074mL10mM0.1654mL0.8269mL1.6537mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(4.13mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(4.13mM);ClearsolutionBIOLOGICALACTIVITY?物活性T-91825(PPI-0903M)?種N-膦酰型頭孢素，TAK-599的活性形式。T-91825對?蘭?陽性和?蘭?性均有活性。體外研究PPI-0903MisveryactiveagainstS.aureus(MIC50=0.25μg/mL),includingmethicillin-resistant(MRSA)strains(MIC50=1μg/mL)[1].PPI-0903Misactiveagainsthetero-vancomycin-intermediateS.aureus(100strains),withMIC50srangingfrom0.25to4μg/mL[1].體內(nèi)研究AK-599(20mg/kg;s.c.threetimesadayfor2days)decreasesthebacterialcellcountsinlungsmorethan99.9%inamousepneumoniamodelcausedbyMRSA[2].REFERENCES[1].SaderHS,et,al.AntimicrobialactivityandspectrumofPPI-0903M(T-91825),anovelcephalosporin,testedagainstaworldwidecollectionofclinicalstrains.AntimicrobAgentsChemother.2005Aug;49(8):3501-12.[2].IizawaY,et,al.InvitroantimicrobialactivityofT-91825,anovelanti-MRSAcephalosporin,andinvivoanti-MRSAactivityofitsprodrug,TAK-599.JInfectChemother.2004Jun;10(3):146-56.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel: